April 17, 2015 / 12:00 PM / 3 years ago

BUZZ-Oncolytics Biotech Inc: Orphan drug status for drug

** Canadian cancer drug developer’s U.S.-listed shares up 14 pct at 79 cents premarket

** Says its experimental drug Reolysin gets orphan drug status from U.S. FDA

** Drug being developed for treating malignant glioma, a type of tumor that affects the brain and spine

** Orphan status, granted to drugs developed to treat rare diseases, gives developer several incentives including seven-year marketing exclusivity in U.S.

** Up to Thursday’s close, stock had fallen 54 pct in the past 12 months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below